Aytu BioPharma, Inc. (AYTU) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• AYTU Q2 2026: Exua Launch Engages 100+ Prescribers, Signals Early Brand Traction
  June 15, 2026
• AYTU Q3 2026: Exua Prescriptions Jump 51% as Launch Accelerates Beyond Core Markets
  May 14, 2026
• AYTU Q4 2025: $10M Exua Launch Investment Signals Strategic Pivot Beyond ADHD Volatility
  September 24, 2025
• AYTU Q1 2025: Pediatric Revenue Jumps 54% as ADHD Baseline Scripts Expand
  November 13, 2024
• AYTU Q4 2024: ADHD Scripts Climb 26% as Pediatric Recovery Signals Portfolio Rebound
  September 26, 2024
• AYTU Q3 2024: ADHD Portfolio Soars 49% as Specialty Pharma Transformation Nears Completion
  May 15, 2024
• AYTU Q2 2024: ADHD Portfolio Revenue Jumps 49% as Consumer Health Exit Reshapes Profitability
  February 14, 2024
• AYTU Q1 2024: ADHD Net Revenue Climbs 31% as Rx Segment Anchors Margin Expansion
  November 14, 2023

Browse all companies